Work

1150TiP A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination

Year: 2021

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.791

Authors: K.A. Margolin, R. Korn, M. Farwell, M.A. Postow, D. Hays, I.A. Wilson, W.H. Le

Institutions: City Of Hope National Medical Center, City of Hope, ImaginAb (United States), University of Pennsylvania, Memorial Sloan Kettering Cancer Center, Central Arkansas Radiation Therapy Institute

Language: English

Topic: Radiopharmaceutical Chemistry and Applications

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3201719454

FWCI:

Cites:

Cited by: 1

Related to: 10